These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 31230400)

  • 1. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
    Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
    Romei C; Elisei R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
    Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
    Ibrahimpasic T; Ghossein R; Shah JP; Ganly I
    Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 12. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
    Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
    In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid Cancer.
    Zhang L; Ren Z; Su Z; Liu Y; Yang T; Cao M; Jiang Y; Tang Y; Chen H; Zhang W; Gong R; Wei T; Peng Y; Liu B; Zhang W; Yang L; Hu Y; Li Z; Zhu J; Xu H; Shu Y; Luo H
    J Clin Endocrinol Metab; 2021 Mar; 106(4):988-998. PubMed ID: 33428730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
    Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
    Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
    [No Abstract]   [Full Text] [Related]  

  • 16. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
    Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
    Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
    Deeken-Draisey A; Yang GY; Gao J; Alexiev BA
    Hum Pathol; 2018 Dec; 82():140-148. PubMed ID: 30075157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
    Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
    Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
    Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.